VIP is unusual in this library: a completely real, physiologically central human neuropeptide, prescribed as a compounded nasal spray by a passionate clinical niche, carrying a pharmaceutical history of near-misses rather than approvals. It deserves neither the dismissal skeptics give it nor the certainty its protocol communities claim. Here is the middle, documented.
What VIP is
Vasoactive intestinal peptide is a 28-amino-acid neuropeptide your body produces throughout the gut, brain, lungs, and immune system: it relaxes smooth muscle, modulates inflammation, supports circadian signaling, and regulates immune tone. Its receptors sit on most immune cell types. Nothing about the molecule is fringe; the fringe questions are about supplementing it.
The pharmaceutical near-miss file
VIP as a drug has been tried seriously: aviptadil (synthetic VIP) reached late-stage COVID-era trials for respiratory failure under an emergency framework and did not demonstrate efficacy convincingly enough for approval; earlier programs explored pulmonary hypertension and sarcoidosis with the same arc of biological plausibility outrunning trial results. The molecule keeps earning trials and keeps missing endpoints, which is a meaningful data point in both directions.
The CIRS protocol world
Most real-world VIP use follows the Shoemaker protocol for chronic inflammatory response syndrome (CIRS), the contested mold-illness framework: compounded VIP nasal spray (typically 50 mcg per spray, four times daily) as a late-stage step after exposure removal and lab normalization. The honest status: CIRS itself is not a recognized diagnosis in mainstream medicine, the protocol's evidence is observational and practitioner-published, and the patient community reporting benefit is large and sincere. All three facts coexist. VIP here is prescription-compounded through pharmacies, a firmer legal footing than research vials, resting on a diagnosis mainstream medicine has not accepted.
Practicalities and cautions
- Route: compounded nasal spray dominates; injectable VIP is rare outside research.
- Documented sensitivities: transient blood-pressure effects and flushing (it is, after all, vasoactive); protocol literature emphasizes starting only after specific labs.
- Product reality: potency of compounded VIP is pharmacy-dependent, and the peptide is fragile; refrigeration and short beyond-use dates apply.
- Evidence posture: treat VIP as a physiologically serious molecule inside an evidentially unsettled protocol, and any clinician prescribing it should be able to explain both halves of that sentence.
Frequently asked questions
What is VIP peptide used for?
In mainstream research: airway, inflammatory, and circadian biology, with failed late-stage trials in respiratory disease (aviptadil). In clinical practice: primarily compounded nasal spray within CIRS/mold-illness protocols, an observational-evidence niche outside recognized diagnosis frameworks.
Is VIP FDA approved?
No VIP product holds FDA approval; aviptadil's COVID-era emergency-framework trials did not lead to one. Use runs through compounding pharmacies under prescription, which is a legal lane, resting on contested clinical territory.
What is the typical VIP dosage?
The dominant protocol uses a compounded nasal spray at 50 mcg per spray, commonly four times daily, introduced late in the Shoemaker sequence after specific lab criteria. That is protocol convention from the CIRS community, not a trial-validated dose.